Montreal, QC—March 18th, 2019— Altius Healthcare, a division of the Devonian Group, has chosen energi PR as its PR Agency of Record for Purgenesis, its specialty line of evidence-based skin care products.  The product will be available exclusively through dermatologists and medical spas across the country.

energi-PR logo
energi-PR logo

“Being able to understand and communicate the science behind our product was a deciding factor in working with energi PR”, said Sybil Dahan, President of Altius Healthcare. “Our messages to consumers, and our distribution through skin care experts requires layers of expertise, not only in terms of the traditional promotion of beauty products, but a solid appreciation of our evidence.”

energi PR specializes in consumer health and wellness and medical science communications. Their decades of experience in dermatology, skincare and medical aesthetics includes work for Proctor & Gamble beauty brands, Galderma Canada, Bausch Healthcare (formerly Valeant), CoverFX, FACES and Clarion to name but a few.

We are excited to be working with the Altius team in bringing this novel product line to market and to deploying our experience across the spectrum of skin health,” said Carol Levine, CEO of energi PR. “The upcoming product reveal will challenge our team to bring the scientific evidence forward in a way that is relevant and meaningful. Canadians have repeatedly confirmed their trust of doctors when it comes to their health and we look forward to helping consumers get the best advice and the best products.”


About Altius Healthcare Inc.


Based in Concord, Ontario, Altius Healthcare, division of Devonian Health Group Inc., is a specialty pharmaceutical company with a primary focus of acquiring and in-licensing safe and innovative medicines and healthcare products designed to help people of all ages live healthier lives. Altius then leverages its expertise in the commercialisation activities required to successfully launch and distribute these medicines in Canada. The team’s diverse experience and expertise draws from nearly 40 years of producing, importing, marketing and distributing branded and generic medicines.

For more information, visit


About Devonian Health Group Inc.
Devonian Health Group Inc. is a late stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2013 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Acquired in 2018, Altius Healthcare Inc., its commercialization partner, brings opportunities for further diversification and growth potential. Devonian is traded publicly on the TSXV Exchange (TSXv:GSD).
For more information, visit


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.